<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30200120</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>17</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>36</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: A meta-analysis.</ArticleTitle>            <Pagination>                <MedlinePgn>e12176</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000012176</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The neutrophil-to-lymphocyte ratio (NLR) has been reported to possess significant prognostic value in multiple types of cancer. We conducted a meta-analysis to evaluate the prognostic value of pretreatment NLR in soft tissue sarcoma (STS).</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature search through April 2018 was conducted to identify studies evaluating the prognostic value of the pretreatment NLR in STS patients. The end points were overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and clinicopathological parameters. All statistical analyses were conducted with Stata 13.0.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Fourteen cohorts with 2820 patients were analyzed. Elevated NLR was significantly correlated with worse OS [hazard ratio (HR): 1.59, 95% confidence interval (95% CI): 1.28-1.97, P &lt; .001] and DFS/PFS (HR = 1.28; 95% CI = 1.12-1.47; P &lt; .001). In addition, elevated NLR was highly correlated with age (≥ 65 years), tumor size (&gt;5 cm), tumor depth (deep), Grade (G3), and TNM stage (III-IV).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overall, pretreatment NLR could be an adverse prognostic biomarker for STS.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Gang</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, Thyroid Surgery, Pancreatic Surgery, Huangshi Central Hospital of Edong Healthcare Group, Hubei Polytechnic University, Huangshi.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ke</LastName>                    <ForeName>Li-Chi</ForeName>                    <Initials>LC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, Thyroid Surgery, Pancreatic Surgery, Huangshi Central Hospital of Edong Healthcare Group, Hubei Polytechnic University, Huangshi.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sun</LastName>                    <ForeName>Sheng-Rong</ForeName>                    <Initials>SR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D017418">Meta-Analysis</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Trials. 2007 Jun 07;8:16</RefSource>                <PMID Version="1">17555582</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2016 Dec 23;6:39862</RefSource>                <PMID Version="1">28008988</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Clin Oncol. 2018 Apr;23(2):368-374</RefSource>                <PMID Version="1">29086877</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Immunol Ther Exp (Warsz). 2001;49(1):63-9</RefSource>                <PMID Version="1">11266093</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2014 Apr;11(4):187-202</RefSource>                <PMID Version="1">24642677</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomarkers. 2012 Sep;17(6):539-44</RefSource>                <PMID Version="1">22793493</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2010 Mar 19;140(6):883-99</RefSource>                <PMID Version="1">20303878</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Stat Med. 1998 Dec 30;17(24):2815-34</RefSource>                <PMID Version="1">9921604</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Immunol. 1985 Jan;134(1):230-4</RefSource>                <PMID Version="1">3871101</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Immunol. 1987 Oct 1;139(7):2406-13</RefSource>                <PMID Version="1">2821114</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2017 Mar;18(3):e166-e175</RefSource>                <PMID Version="1">28271871</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gastroenterology. 2010 Jun;138(6):2101-2114.e5</RefSource>                <PMID Version="1">20420949</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Immun. 2007 Feb 21;7:4</RefSource>                <PMID Version="1">17311363</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2018 Feb 12;9(5):807-815</RefSource>                <PMID Version="1">29581759</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2016 Apr 13;11(4):e0152500</RefSource>                <PMID Version="1">27073890</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2011 Mar 4;144(5):646-74</RefSource>                <PMID Version="1">21376230</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2014 Mar;21(3):778-85</RefSource>                <PMID Version="1">24306668</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109</RefSource>                <PMID Version="1">15061599</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cesk Patol. 2014 Apr;50(2):64-70</RefSource>                <PMID Version="1">24758500</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Sep 18;8(58):98135-98147</RefSource>                <PMID Version="1">29228679</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12</RefSource>                <PMID Version="1">25210080</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Gynecol Cancer. 2011 May;21(4):717-21</RefSource>                <PMID Version="1">21543933</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Manag Res. 2017 Sep 28;9:443-451</RefSource>                <PMID Version="1">29033609</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2013 Oct 1;109(7):1839-47</RefSource>                <PMID Version="1">24008661</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Surg. 2015 Jul;210(1):111-6</RefSource>                <PMID Version="1">25586599</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2009 Oct 1;125(7):1640-8</RefSource>                <PMID Version="1">19569243</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Oncol. 2012 Sep;29(3):1817-26</RefSource>                <PMID Version="1">21678026</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2003 May 15;97(10):2530-43</RefSource>                <PMID Version="1">12733153</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Res. 2018 Mar;38(3):1491-1497</RefSource>                <PMID Version="1">29491077</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Thromb Res. 2010 Apr;125 Suppl 2:S39-43</RefSource>                <PMID Version="1">20434003</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Head Neck. 2016 Jul;38(7):1074-84</RefSource>                <PMID Version="1">26879675</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2008 Jul 24;454(7203):436-44</RefSource>                <PMID Version="1">18650914</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World J Surg Oncol. 2016 Apr 29;14:127</RefSource>                <PMID Version="1">27125872</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2003 Jan 20;103(3):335-43</RefSource>                <PMID Version="1">12471616</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2017 Jul 20;12(7):e0181787</RefSource>                <PMID Version="1">28727824</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2015 Oct 02;15:648</RefSource>                <PMID Version="1">26432433</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Apr 20;6(11):9542-50</RefSource>                <PMID Version="1">25865224</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Gastroenterol Hepatol. 2017 Dec;32(12):1975-1981</RefSource>                <PMID Version="1">28295594</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Transl Oncol. 2017 Dec;10(6):942-948</RefSource>                <PMID Version="1">29031130</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2002 Aug;8(8):2553-62</RefSource>                <PMID Version="1">12171883</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Epidemiol. 2010 Sep;25(9):603-5</RefSource>                <PMID Version="1">20652370</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007958" MajorTopicYN="Y">Leukocyte Count</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012509" MajorTopicYN="N">Sarcoma</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30200120</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000012176</ArticleId>            <ArticleId IdType="pii">00005792-201809070-00062</ArticleId>            <ArticleId IdType="pmc">PMC6133428</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>